Kerin Adelson, MD
Associate Professor AdjunctCards
Appointments
Contact Info
Yale Cancer Center
333 Cedar Street, PO Box 208028
New Haven, CT 06520-8028
United States
About
Titles
Associate Professor Adjunct
Biography
Dr. Adelson is an Adjunct Associate Professor and was previously Chief Quality Officer for Yale Cancer Center and Smilow Cancer Hospital. Dr. Adelson graduated from Yale University School of Medicine, completed residency at Mount Sinai Medical Center and Fellowship in oncology at Columbia Presbyterian. In her Quality role, Dr. Adelson focused on improving care coordination for all patients treated in the Smilow network, aligning care with national quality metrics, and developing models to enhance patient involvement in decisions about their cancer-care. Dr. Adelson sits on several national committees including the Southwest Oncology group Cancer Delivery Committee, the National Cancer Care Network Policy Committee and the American Society of Clinical Oncology Health Information Technology Committee.
Appointments
Medical Oncology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Pusztai Lab
- Subset Medical Oncology Faculty
- Yale Cancer Center
Education & Training
- Fellowship
- Columbia University College of Physicians and Surgeons (2007)
- Residency
- Mount Sinai School of Medicine (2003)
- Internship
- Mount Sinai School of Medicine (2001)
- MD
- Yale School of Medicine (2000)
Research
Overview
Dr. Adelson is actively involved in breast cancer clinical research and serves as an investigator on multiple clinical trials.
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Cary Gross, MD
Maureen Canavan, PhD, MPH
Lajos Pusztai, MD, DPhil
Anne Chiang, MD, PhD
Andrea Silber, MD
Roy S. Herbst, MD, PhD
Publications
2024
Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchConceptsEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare useA Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care
Hakim H, Alexander C, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. A Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care. The Permanente Journal 2024, 28: 212-222. PMID: 39269215, PMCID: PMC11404665, DOI: 10.7812/tpp/23.152.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsShared decision-makingOncology cliniciansSDM principlesPerceptions of shared decision-makingImprove health care outcomesPatient-centred care modelComprehensive cancer care centerLeadership buy-inPatient-centered careHealth care outcomesLung cancer careParticipants perceived benefitsHealth care environmentTeam member rolesNon-small cell lung cancer careThematic analysis of interview dataCancer care centerSimulation-based programAnalysis of interview dataCare modelCare outcomesCancer carePatient-centeredPatient experienceCare environmentBuilding Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program
Alexander C, Hakim H, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. Building Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program. The Permanente Journal 2024, 28: 200-211. PMID: 39269220, PMCID: PMC11404653, DOI: 10.7812/tpp/23.160.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsShared decision-makingPractice settingsImplementation of shared decision-makingSDM trainingTraining programSimulation training programMultidisciplinary cliniciansCentered carePatient goalsPost-trainingClinician experienceFocus groupsClinical careSelf-efficacyParticipants' understandingClinician awarenessPostinterventionPilot studyActive participationParticipantsProgram designCareCliniciansBody of evidenceGrowing body of evidencePrognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024, 27: 879-887. PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchAltmetricConceptsGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatientsSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchConceptsSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapyCommunity Health Worker Navigation for Patients With Cancer: It Is Time to Scale up
Adelson K, Rocque G. Community Health Worker Navigation for Patients With Cancer: It Is Time to Scale up. Journal Of Clinical Oncology 2024, 42: 491-493. PMID: 38175984, DOI: 10.1200/jco.23.01723.Peer-Reviewed Original ResearchAltmetric
2022
Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era
Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsSelf-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott W, Chen K, Peters G, Reddy K, Weintraub S, Mougalian S, Adelson K, Evans S. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e340. PMCID: PMC9595452, DOI: 10.1016/j.ijrobp.2022.07.1432.Peer-Reviewed Original ResearchOncology-hospitalist co-management: A model for efficient, high-quality care and education.
Morris J, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Rothberg BE, Adelson K. Oncology-hospitalist co-management: A model for efficient, high-quality care and education. Journal Of Clinical Oncology 2022, 40: 1-1. DOI: 10.1200/jco.2022.40.28_suppl.001.Peer-Reviewed Original ResearchCitationsConceptsEarly discharge ratesReadmission ratesOncologist satisfactionIntervention teamHospitalist comanagementInpatient oncology serviceSmilow Cancer HospitalOutcome metricsHigher readmission ratesLength of stayMultidisciplinary steering groupHigh-quality careInternal medicine hospitalistsIllness scoresOncology teamCancer HospitalComparator groupOncology servicesPatient populationOutcome comparisonsCase volumeImprovement interventionsPDSA cyclesOncologistsPDSA 2
News & Links
News
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- March 11, 2024
Oncology Hospitalists Improve Hospice Transitions for Patients with Advanced Cancers
- July 03, 2023Source: AJMC
Poster Talks Explore How Policy, Payer Incentives Affect Cancer Care, Outcomes
- March 08, 2023
Involving Hospitalists in Inpatient Cancer Care Reduces Patient Stays, Oncologist Stress
Get In Touch
Contacts
Yale Cancer Center
333 Cedar Street, PO Box 208028
New Haven, CT 06520-8028
United States